Novel strategy approach of Doxofylline and Acebrophylline for the management of Respiratory Diseases

Dr. Kamlesh Kumar Pandey; Dr.Vipul Kalley; Mamta Dhamija

Volume : IX, Issue : III, March - 2019

Novel strategy approach of Doxofylline and Acebrophylline for the management of Respiratory Diseases

Dr. Kamlesh Kumar Pandey, Dr. Vipul Kalley, Mamta Dhamija

Abstract :

Among the several diseases, asthma, onchospastic asthma and COPD (chronic obstructive pulmonary disease) are categorized to be a chronic inflammatory disorder of the airways across the globe. As per the Global Asthma Report 2018, more than 339 million people worldwide are affected with this syndrome and prevalence is still rising. Doxofylline is a xanthine derivative which is used in the treatment of asthma, produces stable serum concentrations, hence plasma monitoring is required only in patients with hepatic insufficiency and intolerance to xanthine drugs. Aceophylline is a novel onchodilator which has anti–inflammatory and mucoregulating effect. It is effective in patients with acute or chronic onchitis, chronic obstructive or asthma–like onchitis and recurrence of chronic onchitis and also reduces the frequency of episodes of onchial resistance and reduces the need for β2–agonists and improves indexes of ventilatory function. The present review article is intended to give comprehensive information and to study the efficacy and safety of the doxofylline and aceophylline for the treatment of respiratory diseases.